The office
How we help pharmaceuticals
We occupy the AI office inside a pharma, medical-affairs, or quality organization. Fractional CAIO, Responsible AI Office, CoE, transformation office, board voice, operating model. We sit. We have decision rights. We stay. This is the function, not a systems build.
- in the office
- not on the sideline
- decision rights
- we make the calls
- we stay
- the function continues
- GxP as duty
- not a checklist
The office, not another AI project.
Pharma companies type “AI consulting pharmaceuticals” because something is already on fire. A vendor is in medical affairs. An author is pasting a clinical study report into a browser. Quality asked about a batch record and a promotional claim in the same sentence. Labeling sits. Safety cases pile. Nobody owns the whole of it. That search is honest. What it usually buys is not: a diagnostic that turns into a statement of work, or a product tour dressed as strategy. Pilots still have no kill date. GxP records still move without a named duty. We do not sell that pattern from this page.
arosplatforms occupies the AI function. We sit as fractional Chief AI Officer, Responsible AI Office, AI Center of Excellence, AI Transformation Office, AI Board Advisory, or the AI operating model — sized to the organization, with decision rights, in the rooms that already run quality, medical affairs, and regulatory. We are a Toronto-based firm. We sit with pharma, medical-affairs, and quality organizations wherever those rooms are. Pharmaceuticals is a separate industry from healthcare. We do not audit you to manufacture a build list.
Custom systems — evidence synthesis, regulatory drafting, pharmacovigilance triage — are a separate engagement. That work already has a home: the pharmaceuticals dossier and regulatory filing. If you came here to shop a submission engine, leave this page and go there. If you came here because the seat is empty, stay.
What the office looks like inside a pharma company.
Scroll through it, the screens move with you.
Someone owns what is live this week
Shadow Veeva copilots, a literature tool with no owner, a safety-case experiment, a browser habit on the CSR. The office holds the list and the reasons, so leadership is not managing a pile.
Lit review · 1 TA
Vendor B renewal
Browser copilot · CSR
GxP and residual risk have a name on them
What AI touches, what it must not, what changed since last quarter, written by the person who will take the questions in the room.
AI inventory this quarter, against the mandate.
three pilots, no quality owner
Browser tool killed. Batch-record path named.[src]
A weekly rhythm the function can run on
Exceptions, vendors, shadow tools, and the quality draft in one operating loop. The officer is in it every week, not at the readout.
Lit review · 1 TA
Vendor B renewal
Browser copilot · CSR
How the function shows up.
Fractional CAIO
The AI agenda for the pharma, medical-affairs, or quality organization, owned by one seat, debated with the CEO and quality, not crowdsourced across Slack and a vendor lunch.
Responsible AI Office
Exceptions, residual risk to quality, and who can stop a launch that would touch a batch record or a submission. Governance as an officer’s duty, not a binder.
Center of Excellence
The door shadow Veeva tools and medical-affairs vendors have to walk through. Intake, standards, reuse, kill-criteria. The unit, not a standup workshop.
Transformation office
Fund, kill, and report the portfolio of AI workstreams. A program office that stays after the first steering slide.
Board advisory
The pack, the committee, director education. A standing board voice on GxP, residual risk, and inspection readiness — not the operating CAIO.
Operating model
Who may build, who approves a go-live into Veeva or the QMS, who kills a pilot. Living decision rights. Not a RACI left in a share drive.
In the rooms, then running the function.
Take the office
We agree the mandate, the rooms we sit in, and who we sit with — CEO, medical affairs, quality, regulatory. You get an occupied function, not a kickoff deck.
First 30 days, in the rooms
We join the meetings that already run the organization. We learn the portfolio by owning it: shadow tools, vendor pilots, quality questions, the batch records and filings that are already moving.
First 90 days, running the function
AI has an owner. Pilots have a yes, a no, or a kill date. Quality and medical affairs have a person who will stand behind the answer. The quality pack has a name on it.
First 180 days, the function holds
The office is not a project that ends. We stay. Cadence, exceptions, and decisions compound because someone is still there to hold them.
Results you can measure.
The AI agenda
one office, one story for the CEO, quality, and medical affairs
Pilots and vendors
yes, no, or a kill date — not another innovation lab
The function
the office is still there after the first quarter
The people who need the seat filled.
CEO, quality, operating partner
The CEO or quality lead that needs an owner
AI is already in the building and already on the agenda. You need an office this month, not a search that takes three quarters and a $400k hire you will not make.
Medical affairs, regulatory, PV
Medical affairs or regulatory holding the bag
You already own the science, the filing, or the safety case. You do not own the AI agenda across those lines. You want a counterpart who will sit with you, not a vendor who will sell past you.
If you want a SOW
Not for teams shopping a filing engine
If the real ask is “build us regulatory drafting, evidence synthesis, or a PV RAG,” this is the wrong page. That is systems work. We occupy the office. We do not sell the implementation from this seat.
Why pharma searches “AI consulting pharmaceuticals” and still has no owner
The query is a symptom. A CEO, a head of quality, or a medical-affairs lead types it because the organization can feel that AI has arrived and that nobody is in charge of it. What they get back is a market that is very good at sounding like an owner and very bad at sitting in the chair.
The search is honest. The category is not.
“AI consulting pharmaceuticals” is what you type when you cannot yet name the job. You know you do not want another chatbot demo. You know you cannot hire a full-time Chief AI Officer this year. You know quality will ask again. The results are strategy decks, platform partners, and implementation shops that begin with a current-state assessment because that assessment is how they find the build. The organization gets activity. It does not get an owner. An owner kills a pilot on a Friday, refuses a vendor on a Wednesday, and tells the quality committee the truth on a Thursday. If your last engagement ended with a roadmap and a vacuum, you bought the category, not the office.
The empty seat is already costing you
No officer does not mean no AI. It means AI without an owner: a literature tool in one therapeutic area and a different one in a second, a Veeva add-on medical affairs bought off a badge, an author pasting a CSR into a public model, a quality packet with a hopeful paragraph and no inventory. We will not invent a dollar figure for that drift. Across the firm we publish 40+ systems shipped, 6.2x median ROI, and 3 weeks to first value — production figures, not a promise that occupying the office prints a return. The comparison is simpler: pay for an office, or keep paying for the absence of one.
Why the hire does not happen
A CAIO who can sit with a pharma CEO and a quality committee is a real executive. The public market for that hire is the same band we already publish on the Chief AI Officer page: full-time base in the mid-six figures, a search that takes quarters. Most organizations on this page will not fill that hire this year. They still have Monday’s meeting. Fractional is how the office exists anyway: a slice of an officer’s week, with rights that stick.
What we will not do with that search
We will not take “AI consulting pharmaceuticals” and translate it into a four-week diagnostic whose commercial purpose is to feed our engineers. We offer AI strategy advisory for pharmaceuticals as systems-adjacent strategy when that is the real ask — a roadmap, not the chair. We offer readiness work when that is the real ask. This page is the chair. If the first serious question you are asked is “what should we build?”, you are talking to a builder. We will ask who decides, and what happens if we say no.
Veeva, the browser, and the work that already happens without you
By the time leadership searches for help, AI is already in the building. It did not wait for a steering committee. It arrived as a browser tab, a “free” copilot, a vendor that a therapeutic area invited in, and a well-meaning author who wanted the module done before the filing clock.
Shadow AI is not a curiosity. It is the portfolio.
In a pharma company the unofficial portfolio is usually larger than the official one. People paste a CSR paragraph into a consumer model because the official tool is slow. A medical writer summarizes a study in a window with no validation path. A PV analyst drafts a case narrative without telling quality. A brand team runs a promotional claim through a tool that will train on it. None of this shows up in the innovation inventory. The office treats it as a portfolio, not a scolding: live, shadow, spend without an owner.
The stack is not the strategy
Veeva Vault, Argus, the CTMS, the QMS — the stack is where the work is written down. It is not an AI operating model. Platform vendors will sell copilots. That does not make the vendor the CAIO. Someone still has to decide which copilots may run, on which records, with which review, and what happens when the suggestion is wrong. We sit with quality and medical affairs on that judgment. We do not pretend the vault is the office, and we do not replace it.
The browser is a control problem
A surprising amount of “pharma AI” is a person and a prompt. That is a decision-rights issue, not a lunch-and-learn. If nobody can forbid a class of use, it continues. If nobody can grant a narrow exception with a log, people take the exception themselves. The Responsible AI Office exists so those sentences have a door, next to quality and regulatory. Killing a browser habit is part of the seat. So is keeping an unfashionable tool that is actually under a validated path. Taste is not the job.
Vendors will fill any vacuum
If the office is empty, the vendor meeting is the office. Every salesperson will offer to be your strategy. A company with an officer should be harder to sell to, not easier. We run vendor decisions as an officer: the problem, the alternative we already own, the contract, the exit. Killing a vendor is part of the seat. So is keeping one that works.
GxP, the QP, and the questions that already have a meeting
Pharma boards and quality committees are not asking for a demo. They are asking what we are doing, what it costs, what could go wrong for a batch or a filing, and who is accountable. Those are officer questions. They land in quality, in medical affairs, in regulatory, and in the same pack that already carries inspection and cyber.
The questions are already on the calendar
What AI touches a batch record or a Module 2 draft. Whether a suggestion can change a label claim. Whether we can reconstruct who saw what. Whether a vendor will sit in a validated environment. Whether last quarter’s paragraph is still true. Those are GxP and residual risk — old categories applied to a function with no name on it. AI Board Advisory is the standing voice in that pack. It is not the operating CAIO. If a pilot should die, the pack says so. Quality has a person, not a program.
Batch release is not a use case for this page
Quality exists because a missed figure can hold a batch or reopen a filing. AI inherits that. A batch record that invents a deviation close is a quality event waiting for a signature. A labeling suggestion that hides a conflict is a regulatory event with a clock on it. The office does not “do batch release.” It makes sure AI is a named line: what may draft, what must be reviewed, what may never decide. If you want the record read, that is the systems dossier. If you want someone who will refuse a go-live because the review path is theater, that is this office.
Quality is not a slide after go-live
The QP and the quality lead do not need another RACI. They need a counterpart who will stop a launch, grant a narrow exception, and take residual risk to the committee. That is the Responsible AI Office in a GxP setting, beside quality and regulatory. When a control program has to be built, the officer commissions it — including AI governance and compliance for pharmaceuticals or someone else. The office lives with the risk until then. That is the difference between a checklist and a duty.
Aros sits in the pack. We do not perform it.
We will not invent a client name, a molecule, or a quote. The proof we are allowed to carry is already on the site: 40+ systems shipped, 6.2x median ROI, 3 weeks to first value on systems work, and the dossier’s weeks-to-hours evidence reviews and 100% of actions logged — figures that belong to systems pages, not to this office. If you need a case narrative for filings, read regulatory filing.
Batch records and GxP as an officer duty, not a checklist
Most pharma AI pages treat GxP as a feature list: validation, Part 11, role-based access, an audit log. Those things matter. They are not the job of this page. The job is the duty: who may let a model see a batch record, who may grant the exception, who tells quality when the exception is residual risk, and who is still there when it goes wrong.
A checklist is a deliverable. A duty is a seat.
A project can produce a GxP alignment memo. An officer has to sleep: an inventory of what touches batch records and submissions, a path for high-risk uses, a named refusal that can stop a launch, and a weekly habit of exceptions. If you want the binder, that is systems work. If you want the person who holds the regime after the binder is filed, that is the office.
Minimum necessary is a decision, every week
What the model may see is a standing judgment: this workflow, this role, this field, this record type. Quality already thinks that way about people. The AI office makes them think that way about systems. When someone asks for “the whole batch history in the prompt,” the answer is no, or a narrower yes with a log.
Logging is not the same as owning the log
The systems dossier already says 100% of actions logged. That is a property of a build. This page is about who reads the log and what happens when it shows a use nobody approved. An empty office can have perfect logs. Nobody is looking.
We do not sell the control plane from the chair
If the organization needs retrieval over the literature and the vault, that is RAG and knowledge systems for pharmaceuticals. If it needs agents on intake or case packets, that is agents and automation for pharmaceuticals. If it needs a governed control program written down and operated as engineering, that is governance for pharmaceuticals. The officer may commission any of those, or none. Engineering is not the product of occupying the office.
Regulatory, medical affairs, and safety cases are why the seat is empty
Authors did not ask for an AI office. They asked for the afternoon back. Medical affairs did not ask for a CAIO. They asked for a literature review that does not sit for a month and a claim that does not reopen. Those are real pains. They are also how empty seats get filled by products.
The weeks-to-hours figure is already published
The pharmaceuticals dossier already carries the figures we will not invent here: weeks-to-hours evidence reviews, cited outputs, 100% of actions logged, 3 weeks to a first workflow. Regulatory filing carries the 30 to 50 percent drafting-time family. They belong to systems. They do not become a promise that sitting in the office writes the module. When a CEO says filings are drowning, the drowning is the symptom; the empty seat is why every vendor gets a pilot and none of them have a kill date. The office is how those purchases become a portfolio instead of a pile.
A copilot does not appoint an owner
Cited regulatory drafting can be the right system. A literature reader can be the right system. A PV triage assistant can be the right system. None of them decide what else is allowed to exist, sit with quality when the next vendor arrives, or kill the browser tab. If you are shopping those builds, use the dossier and regulatory filing. If you are using filing pain to start a funnel that becomes a SOW, you are in the pattern we refuse here.
Medical affairs is a portfolio problem dressed as a workflow
MSL briefs, scientific exchange, MLR packets, a PubMed habit — that is workflow. Who bought the tool, who may buy the next one, whether the vendor’s model sees more of the CSR than the brief requires — that is the office. We will not assemble your MLR packets from this engagement. We will decide whether packet assembly is a thing the organization is doing on purpose.
Pharmacovigilance is not a license to skip the seat
The fastest way to make PV worse is to add three tools and call it signal. Case intake, duplicates, expedited reports — the dossier already speaks that language as systems work. The office exists so “signal” has a definition, an owner, and a date we will know if it worked. If it did not, the officer kills it.
How the function shows up in a pharma, medical-affairs, or quality organization
We do not invent a seventh pharmaceuticals-only title. The six function seats already exist. In a pharma, medical-affairs, or quality organization they have a particular grain. You may need one. You may need two. You do not need a doorway that pretends each seat has its own /pharmaceuticals mini-site. Function seats have no industry pair pages. That is a rule, not an omission.
Chief AI Officer
In a pharma company the Chief AI Officer sits with the CEO, quality, and often medical affairs. The agenda is what we will do with AI this quarter across regulatory, quality, and medical — and what we will not. Spend hides in vault add-ons, cloud, and therapeutic-area cards. The CAIO owns the number and the refusal. This is the officer’s chair, not a medical-writing hire and not a build lead.
Responsible AI Office
In a GxP organization the Responsible AI Office is who can say no when a model would touch a batch record, a submission, or a safety case. Exceptions have a door. Residual risk has a line quality can see. This is the living regime beside quality and regulatory, not a validation memo and not a policy workshop.
AI Center of Excellence
In a pharma company the AI Center of Excellence is the door. Shadow Veeva copilots, medical-affairs vendors, a TA-level side project — they walk in here or they do not. Intake, standards, reuse, kill-criteria. If the queue is real and the kills are real, you have a CoE. If not, you have a newsletter.
AI Transformation Office
The AI Transformation Office funds, kills, and reports a portfolio of workstreams — a filing experiment, a literature rollout, a PV triage agent — without becoming the builder. In a pharma company it sits with the COO and quality’s cadence. It stays after the first steering slide. It is not a strategy deck, and it is not the CAIO.
AI Board Advisory
AI Board Advisory is the standing board voice: the pack, the committee, director education. On a pharma board the grain is GxP, residual risk, and inspection readiness. It is not the operating seat. If you need the officer in Monday’s meeting, that is the CAIO.
AI Operating Model
The AI operating model is who may build, who approves a go-live into Veeva or the QMS, and who kills a pilot. In a multi-site company it is the difference between a governed function and a collection of therapeutic areas. Living decision rights, not a RACI in a share drive.
Who this is for, and who should leave the page
We would rather lose a conversation than take an office we cannot hold. The fit is specific. If you are not in it, the honest next step is a different page — often the systems dossier — or a different firm.
Who this is for
A CEO, chair, or operating partner of a pharma, medical-affairs, or quality organization who wants an AI office and will give that office rights. A quality, medical-affairs, or regulatory lead who is already holding the bag and wants a counterpart, not a vendor. A quality committee that asked about GxP and residual risk and received a paragraph. An organization that already has AI in the building — licenses, vault copilots, shadow browser use — and no one who owns the whole of it.
It is also for leadership that wants the truth more than the theater. If you want an office that will kill work, refuse vendors, and tell quality the unvarnished version, we can do that. If you want a mascot for the inspection narrative, we cannot.
Who this is not for
Anyone shopping for a custom-build, an “AI OS,” regulatory drafting, evidence synthesis, or a PV RAG and using office language to start the funnel. Anyone who wants an audit, a gap list, and a proposal to close the gaps. Anyone who will not grant decision rights. Anyone looking for a hire. Anyone whose real problem is a demo by Thursday.
It is also not for an organization that already has a strong CAIO or RAI office and wants extra hands. That is staff augmentation. We are not extra hands. We are the seat. If the seat is filled, we should not be in it.
Where the systems people should go
If you want what we build in the sector, start at the industries hub and open Pharmaceuticals. From there: regulatory filing and the systems doorways — strategy, governance, RAG, agents. Those pages sell the work. This page sells the office. Do not ask this page to do both.
30 / 90 / 180 days in a pharma organization
Pharma companies ask for a 30 / 90 / 180 because they want to know what changes. Here is what changes when you bought the office, not a diagnostic. There is no phase called “discover the gaps,” and no phase called “build the filing system.” There is a person in the chair, and the chair gets more real.
The first 30 days: we are already the office
Week one is the mandate: decision rights, meetings, spend we can touch, the name on the quality or board pack. We sit with the CEO, quality, and medical affairs. We take the keys that exist — vendors, invoices, pilots, browser habits, contracts — the way a head of quality takes a CAPA portfolio. By month’s end we are in the rooms and we have made at least one real decision so the seat is not ceremonial. We will not publish a maturity score or produce a backlog for our engineers.
The first 90 days: the function is being run
There is a standing AI agenda. The portfolio is shorter, because some things died — often a shadow tool, often a vendor that should never have been in the vault. Vendors have a status. Pilots have kill dates. Exceptions have a door. At 90 days we can tell quality what the organization is doing with AI, what touches batch records, and what we will decide next. If we cannot, we have been busy, not in the seat.
The first 180 days: the function holds
The office should now be boring in the way a good quality function is boring: cadence, rights, a pack, fewer surprises. New ideas and renewals go through the office. If the organization has grown into a full-time hire, we will say so. If it has not, we stay. One hundred and eighty days is not the end of a project, and it is not the moment we reveal systems we would like to build.
Book the conversation about the office
If you need an AI function in a pharma, medical-affairs, or quality organization, and you are not going to hire a full-time officer this year, the honest move is to put someone in the chair anyway. arosplatforms will occupy that office. We will sit with your CEO, your quality lead, your medical-affairs lead, and your regulatory head. We will own the agenda. We will make the calls. We will stay.
If you need a plan, an assessment, or a system — filings, evidence, retrieval, agents — say that. Those are other pages, and we will not pretend this one is a doorway to them. Start at the pharmaceuticals systems dossier or the industries hub. If you need the office, book a conversation about putting us in it. That is the only ask on this page.
Seats, systems, and the dossier.
The office is this page. The six seats are the function. The dossier and the pages below are systems work — a separate engagement. Healthcare, real estate, and legal are sibling occupy-function pages, not extra sectors.
The rooms and systems we sit with
Frequently asked.
It means arosplatforms sits as the AI function inside your pharma, medical-affairs, or quality organization: agenda, portfolio, exceptions, vendors, and the quality conversation, with decision rights, for as long as the office is needed. It is not a workshop. It is not a maturity score. It is not a doorway into a custom-build. The six seats — Chief AI Officer, Responsible AI Office, AI Center of Excellence, AI Transformation Office, AI Board Advisory, and AI operating model — are how that function shows up. We take the mandate. We show up. We stay.
Put Aros in the AI office
Book a conversation about occupying the AI function in your pharma, medical-affairs, or quality organization. We sit with your CEO, quality, and medical affairs. We make the calls. We stay.